Locomotion and stereotypy induced by scopolamine: contributions of muscarinic receptors near the pedunculopontine tegmental nucleus

Brain Research
A MathurJ S Yeomans

Abstract

In this study, we test whether blockade of muscarinic receptors near mesopontine cholinergic cell groups may contribute to locomotor activation induced by scopolamine. Unilateral or bilateral injections of scopolamine (10-150 micrograms) into the pedunculopontine tegmental nucleus (PPT) increased horizontal locomotion by 2-15 times in a dose-related way. Unilateral or bilateral injections of scopolamine into the PPT increased stereotypic behaviors (such as sniffing in one location or over large areas), self-biting and grooming. Carbachol (4 micrograms) injected into PPT reduced locomotion for 20 min, followed by 70 min of increased locomotion. When carbachol (4 micrograms) was injected into the PPT before scopolamine (3 mg/kg, i.p.), the activating effect of scopolamine was attenuated, but not when carbachol was injected after scopolamine. Therefore, carbachol appears to compete with scopolamine for muscarinic receptors near the PPT that mediate locomotor activating effects of systemic scopolamine. Haloperidol (0.1 mg/kg, i.p.) also attenuated the stereotypy and locomotion induced by scopolamine in the PPT. We hypothesize that scopolamine acts by blocking muscarinic receptors on mesopontine cholinergic neurons, thereby disinhib...Continue Reading

References

Sep 1, 1976·European Journal of Pharmacology·P SetlerG McKenzie
Oct 1, 1992·Naunyn-Schmiedeberg's Archives of Pharmacology·J Grenhoff, T H Svensson
May 1, 1992·Pharmacology, Biochemistry, and Behavior·A Bechara, D van der Kooy
Mar 1, 1990·Brain Research Bulletin·E Garcia-RillR D Skinner
Oct 30, 1990·Neuroscience Letters·M SerafinM Mühlethaler
Feb 1, 1990·British Journal of Pharmacology·C Reavill, I P Stolerman
Jul 1, 1990·Pharmacology, Biochemistry, and Behavior·K Mueller, J L Peel
Sep 1, 1989·British Journal of Pharmacology·P CalabresiR A North
Mar 11, 1985·Brain Research·J S YeomansV McFarlane
Dec 1, 1993·Annals of Neurology·M PocchiariY G Xi

❮ Previous
Next ❯

Citations

May 28, 2013·Behavioural Brain Research·C JacquelinC Strazielle
Feb 13, 2001·Pharmacology, Biochemistry, and Behavior·G CalamandreiE Alleva
Sep 19, 2003·Pharmacology, Biochemistry, and Behavior·Araba ChintohJohn S Yeomans
Jan 19, 2000·Pharmacology, Biochemistry, and Behavior·S R LavioletteJ S Yeomans
Sep 15, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Segev Barak, Ina Weiner
Aug 24, 1999·The European Journal of Neuroscience·T HumbyL S Wilkinson
Jul 17, 2004·Neuroreport·Anthony D Miller, Charles D Blaha
Jun 15, 2015·Pharmacology, Biochemistry, and Behavior·Priya J GhumatkarSadhana Sathaye
May 26, 2010·The European Journal of Neuroscience·John S YeomansSusanne Schmid
Apr 8, 2010·CNS Neuroscience & Therapeutics·Deranda B LesterCharles D Blaha
Feb 27, 2014·Behavioural Brain Research·Lauren K Dobbs, Christopher L Cunningham
May 25, 2015·Neuroscience and Biobehavioral Reviews·Sean P CarruthersSusan L Rossell
Jun 18, 2009·The International Journal of Neuropsychopharmacology·Sebastien CarnicellaPhilippe Oberling
Apr 26, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·Guido AlvesDag Aarsland
Jan 10, 2017·Frontiers in Cellular Neuroscience·Laura WalraveIlse J Smolders
Oct 25, 2017·Journal of Vestibular Research : Equilibrium & Orientation·Phillip AitkenPaul F Smith
Feb 6, 2020·Frontiers in Pharmacology·Nicole Elaine ChambersChristopher Bishop
Oct 17, 2019·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·Cristian Perez-FernandezFernando Sánchez-Santed
Jan 12, 2021·The European Journal of Neuroscience·Nicole E ChambersChristopher Bishop
Mar 2, 2021·Behavioural Brain Research·Daniel J FosterP Jeffrey Conn
May 20, 2009·Behavioural Brain Research·Lisbeth E Gómez-Martínez, Rafael Cueva-Rolón

❮ Previous
Next ❯

Related Concepts

Related Feeds

Amygdala and Midbrain Dopamine

The midbrain dopamine system is widely studied for its involvement in emotional and motivational behavior. Some of these neurons receive information from the amygdala and project throughout the cortex. When the circuit and transmission of dopamine is disrupted symptoms may present. Here is the latest research on the amygdala and midbrain dopamine.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here